MetaVia Inc (MTVA)

Form 8-K - Current report

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity

MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor...

BioStem Technologies Announces Appointment of Three New Members to its Board of Directors

POMPANO BEACH, Fla., June 09, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Form 8-K - Current report

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential

MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting...

Form 8-K - Current report

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH

MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

DENVER, May 22, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com) – The biotechnology sector continues attracting speculative capital as...